Towards Healthcare
New Chemical Entities (NCE) CDMO Market to Grow at 11.44% CAGR till 2034

New Chemical Entities (NCE) CDMO Market Rising Outsourcing and Advanced Manufacturing

According to market projections, the new chemical entities (NCE) CDMO sector is expected to grow from USD 2.65 billion in 2024 to USD 7.83 billion by 2034, reflecting a CAGR of 11.44%. The new chemical entities (NCE) CDMO market is growing due to its offering hope for managing diseases where existing therapies fall short or are inaccessible. North America is dominant in the market due to increasing pharmaceutical R&D and regulatory support.

Content

  • Insight Code: 6292
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The new chemical entities (NCE) CDMO market stands at USD 2.95 billion in 2025 and is expected to reach USD 7.83 billion by 2034, growing at a CAGR of 11.44% from 2024 to 2034.

North America is currently leading the new chemical entities (NCE) CDMO market due to a vast manufacturing capacity and government support.

Some key players include Cambrex Corporation, Boehringer Ingelheim BioXcellence, PCI Pharma Services, Evonik Industries AG, AMRI (Albany Molecular Research Inc.), and Fujifilm Diosynth Biotechnologies.

A New Chemical Entity (NCE) is a term used in the pharmaceutical industry to describe a compound that emerges from the process of drug discovery. This compound is unique in that it represents a novel structure that has never before been approved for medical use by any regulatory authority around the world.

Ministry of Health and Family Welfare, FDA, WHO, PIB, CDC.
Any Questions